Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cubist Pharmaceuticals Inc announces acceptance of Ceftolozane/Tazobactam new drug application with priority review


Thursday, 19 Jun 2014 04:30pm EDT 

Cubist Pharmaceuticals Inc:Says U.S. Food and Drug Administration (FDA) accepted company's New Drug Application (NDA) for investigational antibiotic ceftolozane/tazobactam with Priority Review.FDA has assigned Prescription Drug User Fee Act (PDUFA) action date of Dec. 21, 2014.Cubist is seeking FDA approval of ceftolozane/tazobactam for the treatment of complicated urinary tract Infections and complicated intra-abdominal infections. 

Company Quote

73.15
0.73 +1.01%
24 Oct 2014